Global TCV Vaccine Market (2022 to 2030)

DUBLIN, April 14, 2022 /PRNewswire/ — The “TCV Vaccine Market – Size, Share, Outlook and Opportunity Analysis, 2022-2030” report has been added to from ResearchAndMarkets.com offer.

Typbar TCV is a typhoid vaccine recommended for the prevention of typhoid fever. Typbar TCV The vaccine works by causing the body to produce its own protection (antibodies) against the bacteria. This vaccine is generally recommended for people traveling to areas where typhoid fever is common.

Ongoing Typbar-TCV studies will provide important data of great value for typhoid fever endemic regions and for incorporation of the vaccine into routine immunization programs in endemic regions such as Asia, Latin America and others to control drug-resistant typhoid fever and the spread of antimicrobial resistance around the world. The World Health Organization recommends the introduction of typhoid conjugate vaccine (TCV) for infants and children over six months of age in countries where typhoid is endemic.

This new policy helps and guarantees access to typhoid vaccination in the communities most affected by the disease, responsible for nearly 12 million infections and 128,000 to 161,000 deaths per year. Typhoid has a disproportionate impact on young children and marginalized populations in most Asia PacificSub-Saharan Africa and parts Latin America and the Middle East which often have outdated, inadequate or unsanitary water and sanitation systems. With supportive global and financial policies in place, typhoid vaccines, in addition to water, sanitation and hygiene interventions, can reach those most in need and reduce the burden of typhoid fever.

Market dynamics

Increase in typhoid prevalence, increase in government initiatives promoting and advancing the development of innovative products, increase in antibiotic resistance and adoption of inorganic growth strategies such as collaboration and agreement, in order to expand their portfolio of products and strengthen their presence in the market. These are the major factors that are expected to drive the growth of the global TCV Vaccines market over the forecast period.

Main characteristics of the study:

  • This report provides an in-depth analysis of the global TCV Vaccines market and provides market size (Million US$) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights into the market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles the leading players in the global TCV Vaccines market based on the following parameters: company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, future strategies and plans.
  • The main companies covered in this study are GlaxoSmithKline PLC, Sanofi SA, Bharat Biotech, PT BIO FARMA and PaxVax, Inc.
  • The information in this report would enable marketers and managing authorities of companies to make informed decisions regarding their future product launches, type upgrade, market expansion, and marketing tactics.
  • The Global TCV Vaccines Market report is targeted at various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants and financial analysts
  • Stakeholders would have an ease in making decisions through various strategic matrices used to analyze the global TCV Vaccines market

Main topics covered:

1. Research objectives and hypotheses

2. Competence of the market

  • Description of the report
  • Market definition and scope
  • Summary
  • Market extract, by vaccine brand
  • Market extract, by distribution channel
  • Market extract, by region
  • Consistent Opportunity Map (COM)

3. Market dynamics, regulation and trend analysis

  • Market dynamics
  • Drivers
  • Constraints
  • Market opportunities
  • Impact analysis
  • Pipeline analysis
  • PEST analysis
  • Regulatory scenario
  • Market trends
  • Highlights
  • Refund scenario
  • Mergers and Acquisitions

4. Global TCV Vaccines Market- Impact of Coronavirus (COVID-19) Pandemic

  • Economic impact
  • Government initiatives

5. Global TCV Vaccines Market, By Vaccine Brand, 2017-2030, (USD Million)

  • Introduction
  • Market share analysis, 2022 and 2030 (%)
  • Annual Growth Analysis, 2018 – 2030
  • Industry trends
  • Ty21a (Vivotive)
  • Introduction
  • Market Size & Forecast, and Annual Growth, 2017-2030, (USD Million)
  • ViCPS (typhim Vi)
  • Introduction
  • Market Size & Forecast, and Annual Growth, 2017-2030, (USD Million)
  • Vi-TT (Peda-typhTM)
  • Introduction
  • Market Size & Forecast, and Annual Growth, 2017-2030, (USD Million)
  • Typbar TCV
  • Introduction
  • Market Size & Forecast, and Annual Growth, 2017-2030, (USD Million)

6. Global TCV Vaccines Market, by Distribution Channel, 2017-2030, (USD Million)

  • Introduction
  • Market share analysis, 2022 and 2030 (%)
  • Annual Growth Analysis, 2018 – 2030
  • Industry trends
  • Audience
  • Introduction
  • Market Size & Forecast, and Annual Growth, 2017-2030, (USD Million)
  • UNICEF
  • Tender (Government)
  • Private
  • Introduction
  • Market Size & Forecast, and Annual Growth, 2017-2030, (USD Million)

7. Global TCV Vaccines Market, by Region, 2017-2030, (USD Million)

  • Introduction
  • Market share analysis, by region, 2022 and 2030 (%)
  • Analysis of annual growth, for regions, 2018-2030
  • North America
  • Market size and forecast, by vaccine brand, 2017-2030, (USD Million)
  • Market size and forecast, by distribution channel, 2017 – 2030, (USD Million)
  • Market size and forecast, by country, 2017 – 2030, (USD Million)
  • WE
  • Canada
  • Latin America
  • Market size and forecast, by vaccine brand, 2017-2030, (USD Million)
  • Market size and forecast, by distribution channel, 2017 – 2030, (USD Million)
  • Market size and forecast, by country, 2017 – 2030, (USD Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • Market size and forecast, by vaccine brand, 2017-2030, (USD Million)
  • Market size and forecast, by distribution channel, 2017 – 2030, (USD Million)
  • Market size and forecast, by country, 2017 – 2030, (USD Million)
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • Market size and forecast, by vaccine brand, 2017-2030, (USD Million)
  • Market size and forecast, by distribution channel, 2017 – 2030, (USD Million)
  • Market size and forecast, by country, 2017 – 2030, (USD Million)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • Market size and forecast, by vaccine brand, 2017-2030, (USD Million)
  • Market size and forecast, by distribution channel, 2017 – 2030, (USD Million)
  • Market size and forecast, by country, 2017 – 2030, (USD Million)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • Market size and forecast, by vaccine brand, 2017-2030, (USD Million)
  • Market size and forecast, by distribution channel, 2017 – 2030, (USD Million)
  • Market size and forecast, by region/country, 2017 – 2030, (USD Million)
  • South Africa
  • central Africa
  • North Africa

8. Competitive Landscape

  • Heat map analysis
  • Market share analysis
  • GlaxoSmithKline PLC
  • Company presentation
  • Product portfolio
  • Financial overview
  • Highlights
  • Market strategies
  • Sanofi SA
  • Company presentation
  • Product portfolio
  • Financial overview
  • Highlights
  • Market strategies
  • Bharat Biotech
  • Company presentation
  • Product portfolio
  • Financial overview
  • Highlights
  • Market strategies
  • PT ORGANIC FARM
  • Company presentation
  • Product portfolio
  • Financial overview
  • Highlights
  • Market strategies
  • PaxVax, Inc.
  • Company presentation
  • Product portfolio
  • Financial overview
  • Highlights
  • Market strategies
  • Analyst Views

9. Branch

For more information on this report, visit https://www.researchandmarkets.com/r/ijajrr

Media Contact:

Research and Markets
Laura Woodsenior
[email protected]

For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900

US Fax: 646-607-1904
Fax (outside the US): +353-1-481-1716

SOURCE Research and Markets

Comments are closed.